RAPT (RAPT Therapeutics, Inc. Common Stock) Stock Analysis - AI Report

RAPT Therapeutics, Inc. Common Stock (RAPT) is a publicly traded Healthcare sector company. As of May 21, 2026, RAPT trades at $58.02 with a market cap of $1.68B and a P/E ratio of -18.19. RAPT moved +0.07% today. Year to date, RAPT is +132.08%; over the trailing twelve months it is +536.18%. Its 52-week range spans $5.67 to $58.02. Analyst consensus is hold with an average price target of $60.00. Rallies surfaces RAPT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What is the AI research view on RAPT?

Rallies AI research for RAPT combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.

RAPT Key Metrics

Key financial metrics for RAPT
MetricValue
Price$58.02
Market Cap$1.68B
P/E Ratio-18.19
EPS$-3.19
Dividend Yield0.00%
52-Week High$58.02
52-Week Low$5.67
Volume11.13M
Avg Volume0
Revenue (TTM)$0
Net Income$-129.87M
Gross Margin0.00%

Latest RAPT News

RAPT Analyst Consensus

15 analysts cover RAPT: 0 strong buy, 4 buy, 11 hold, 0 sell, 0 strong sell. Consensus rating is hold. Average price target: $60.00.

Common questions about RAPT

What is the AI research view on RAPT?
Rallies AI research for RAPT combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
What data powers the Rallies AI report for RAPT?
Rallies AI research for RAPT combines live market data, financials, news, analyst context, hedge fund ownership, politician disclosures, insider activity, and risk factors.
Is RAPT research on Rallies investment advice?
No. Rallies provides research, data, and educational context for RAPT. It does not provide personalized investment advice.
RAPT

RAPT